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ABSTRACT 
Background: Prices of anti-cancer drugs are skyrocking. We aimed to assess the clinical 
benefit of new drugs for treating advanced solid tumors at the time of their approval by the 
US Food and Drug Administration (FDA) and to search for a relation between price and 
clinical benefit of drugs.  
Materials and methods: We included all new molecular entities and new biologics for 
treating advanced solid cancer that were approved by the FDA between 2000 and 2015. The 
clinical benefit of drugs was graded based on FDA medical review of pivotal clinical trials 
using the 2016-updated of the American Society of Clinical Oncology Value Framework 
(ASCO-VF) and the European Society for Medical Oncology Magnitude of Clinical Benefit 
Scale (ESMO-MCBS). Characteristics of drugs and approvals were obtained from publicly 
available FDA documents and price was evaluated according to US Medicare, US Veterans 
Health Administration and United Kingdom market systems. 
Results: The FDA approved 51 new drugs for advanced solid cancer from 2000 to 2015; we 
could evaluate the value of 37 drugs (73%). By the ESMO-MCBS, five drugs (14%) were 
grade one (the lowest), 9 (24%) grade two, ten (27%) grade three, 11 (30%) grade four and 
two (5%) grade five (the highest).  Thus, 13 drugs (35%) showed a meaningful clinical benefit 
(scale levels 4 and 5). By the ASCO-VF which had a range of 3.4 to 67, the median drug 
value was 37 (interquartile range 20 to 52). We found no relationship between clinical benefit 
and drug price (p = 0.9).  No characteristic of drugs and of approval was significantly 
associated with clinical benefit. 
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Conclusion: Many recently FDA-approved new cancer drugs did not have high clinical 
benefit as measured by current scales. We found no relation between the price of drugs and 
benefit to society and patients. 
Key Words: Value-Based Purchasing; Relative Value Scales; Prescription Drugs; Costs and 
Cost Analysis; Neoplasms/drug therapy. 
Key Message:  
A high number of new drugs approved by the FDA between 2000 and 2015 for treating 
advanced solid cancer did not have high clinical benefit as measured by the scales recently 
developed by the ASCO and the ESMO.  A meaningful clinical benefit was observed for only 
35% of evaluable drugs. Clinical benefit score was not associated with the drug price neither 
with characteristics of drugs or of approval. 
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introduction  
The concept of the value of drugs has recently dominated oncology. Massive investments in 
research yielded major advances in the comprehension of tumor biology, which has translated 
to an increase in number of new anti-cancer drugs approved by the US Food and Drug 
Association (FDA). Hence, new anticancer drugs have yielded high expectations from all 
stakeholders. Especially, drugs for personalized medicine — patients to be treated are selected 
on the basis of a predictive (genomic) biomarker — represent great hope for the oncology 
community. [1]   Similarly, first-in-class drugs (relying on a new pharmacological mechanism 
of action) represent a measure of innovation success and could therefore have high value. [2]  
An increasing number of drugs has been approved by using pathways and designations to 
expedite drug approval; [3] these are drugs that are intended for life-threatening conditions 
and unmet medical need.  
The skyrocketing price of oncology drugs has led various stakeholders (patients, physicians, 
third-party payers) to criticize the pricing policies of manufacturers [4] and, combined with 
the high burden of cancer, has highlighted the question of the value of cancer drugs. [5] The 
high price of drugs is often justified by the need to support research and development, but an 
analysis of the most transformative drugs showed that, actually, government-funded academic 
research was the primary source of drug innovation. [6]  
A critical question for the oncology community is how to assess the value of drugs. Two 
important oncology societies have recently taken a step forward in this endeavor: The 
American Society of Clinical Oncology (ASCO) published its Conceptual Framework to 
Assess the Value of Cancer Treatment Options (ASCO-VF), [7] which was updated in 2016, 
[8] and the European Society for Medical Oncology developed its Magnitude of Clinical 
Benefit Scale (ESMO-MCBS) for drugs indicated in the treatment of solid cancer. [9] Both 
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scales have been designed with the aim of evaluating the value of anti-cancer drugs by 
"[balancing] the magnitude of its clinical benefit […] against its cost". [9]  
This study aimed to describe the clinical benefit of new drugs for treating advanced solid 
cancer that were recently approved by the FDA and to search for a relationship between 
clinical benefit and price of drugs and for characteristics associated with clinical benefit.  We 
restricted this study to drugs for treating advanced solid cancer because the (1) ESMO-MCBS 
is applicable only for drugs treating solid cancers and (2) the vast majority of new anticancer 
drugs are indicated in the advanced setting.  
 
methods 
list of drugs 
We included all new drugs (new molecular entities and novel biologics) indicated for treating 
advanced solid cancer that were approved by the FDA between 2000 and 2015.  
description of the ASCO-VF Net Health Benefit (NHB) 
The ASCO-VF NHB has 3 main components: 1) magnitude of treatment effect 2) toxicity, 
and 3) bonus points. [8] The magnitude of treatment effect is assessed by overall survival 
(OS) if reported; if OS is not reported, progression-free survival (PFS) is used; and if neither 
OS nor PFS are reported, overall response rate (ORR) is used. Treatment effect size for OS 
and PFS is quantified by hazard ratios (HR) and difference in median survival time and 
weighted by type of endpoint. For instance, an HR of 0.7 for OS yields 30 points, but the 
same HR for PFS would yield only 21 points.  
The toxicity score ranges from -20 to +20. The value depends on the frequency and severity 
of toxic effects. A null value corresponds to a new drug with similar toxicity as for the 
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control. Negative points are for a new drug associated with high toxicity and positive points 
are awarded if the new drug reduces toxicity as compared to the control. 
If a treatment is associated with long-term benefit, it can be awarded "tail of the curve" bonus 
points (16 points for PFS or 20 for OS). Three other possible bonuses include a ten-point 
bonus for treatments improving cancer-related symptoms, another ten-point bonus for 
improving quality-of-life (QoL), and another ten-point bonus for improving treatment-free 
interval. These bonuses can be cumulative. The sum of the magnitude of treatment effect, 
toxicity, and bonus points gives the net health benefit (ASCO-VF NHB).[8] 
description of the ESMO-MCBS 
The ESMO-MCBS has two main components: 1) a preliminary score based on the clinical 
benefit and 2) modification (upgrade and downgrade) of the primary score based on the 
toxicity and QoL, which yields the final score based on five-point scale ranging from one, 
lowest grade, to five, highest grade. [9] Levels four and five correspond to a meaningful 
clinical benefit.[9, 10]  In the first part, a preliminary score is calculated on the basis of the 
clinical benefit of the drug according to the primary endpoint of the study. The treatment 
effect size is quantified  by either (i) the lower limit of the 95% confidence interval (CI) for 
the HR and by differences in median survival or (ii) by the increase in survival at a fixed time 
(two or three years depending on the median survival time with the standard treatment). When 
HRs and the increase in survival at a fixed time yield different results, the best score is used. 
With OS, the preliminary value ranges from one to four and could be upgraded if the 
treatment improves QoL or reduced grade three to four toxicity affecting daily well-being. 
Hence, the final value for drugs evaluated with OS ranges from one to five. For drugs 
evaluated with PFS, the preliminary value ranges from one to three and could be upgraded 
with the same conditions as for OS. However, the score could be downgraded with increased 
toxicity or if a drug leads to only a benefit for PFS (ie, without a benefit for OS) and fails to 
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show an improvement in QoL. The maximal value for drugs evaluated with PFS is thus four. 
The ESMO-MCBS indicates that levels four and five correspond to ASCO guidelines for 
meaningful clinical benefit. [9, 10] 
grading of the clinical benefit drug by using the ASCO-VF and ESMO-MCBS 
We graded the drugs with the ASCO-VF and ESMO-MCBS based on data from the pivotal 
clinical trials submitted to the FDA for approval and described in the FDA medical review 
(retrieved from Drugs@fda website). Scores were assessed by one investigator and checked 
by a second one, with discrepancies resolved by a senior investigator. 
approval characteristics 
We assessed whether the drug was granted with one of the five FDA pathways and 
designations to expedite drug approval (orphan drug status, fast-track, priority review, 
breakthrough designation, and accelerated approval).  
drug prices 
We re-used data from the DrugAbacus database to obtain the price of drugs in 3 markets: US 
Medicare, US Veterans Health Administration and the United Kingdom. [11] For drugs not 
listed in the DrugAbacus database, we computed the cost in US Medicare terms by using 
publicly available data and the same methods as used in the DrugAbacus database. The 
primary analysis was pre-specified as using prices by the US Medicare system because it had 
the fewest missing values. 
 statistical Analyses 
The association between the clinical benefit of drugs and their characteristics was tested by 
Mann-Whitney-Wilcoxon and Fisher exact tests. We investigated the relation with drug prices 
by simple linear regression. P <0.05 was considered statistically significant. 
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results 
number and characteristics of new drugs 
From 2000 to 2015, the FDA approved 51 new drugs for treating advanced solid tumors 
(Figure S1). Three approvals were discontinued as of October 6, 2016 and thus were removed 
from our sample. Furthermore, we could not assess the value of 11 drugs (23%) because the 
pivotal trial was not a head-to-head RCT, had a non-inferiority design or did not report one of 
the 3 endpoints used in the value scales (OS, PFS, ORR). Thus, we analyzed data for 37 
drugs. The most frequent indications were colorectal (N=6, 16%) and breast (N=6, 16%) 
cancers (Table S1). 
clinical benefit of new drugs  
By the ASCO-VF, the median net health benefit (NHB) of drugs was 37 [interquartile range 
20 to 52; range 3.4 to 66.5] (Table S2 and Figure 1). The median treatment effect score was 
34 [interquartile range 23 to 42] and the median toxicity score was -5 [-13 to -2]. Bonus 
points for a tail on PFS curves were granted for 14 drugs (38%) and for OS curves for four 
drugs (11%); for palliation symptoms for two drugs (5%); and for improvement in QoL for 
four drugs (11%). No drugs received bonus points for treatment-free interval. By the ESMO-
MCBS, five drugs (14%) were grade one (the lowest), 9 (24%) grade two, ten (27%) grade 
three, 11 (30%) grade four and two (5%) grade five (the highest). Thus, 13 drugs (35%) had a 
meaningful clinical benefit (levels four and five). Toxicity assessment downgraded the value 
for two drugs (5%) and upgraded it for one drug (3%).  Quality of life assessment 
downgraded the value for four drugs (11%) and upgraded it for six drugs (16%).  Results of 
assessment of value for each drug are provided in Table 1.  
characteristics associated with drug clinical benefit 
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We found no differences in ASCO-VF scores by innovation degree (first-in-class vs advance 
or addition to class: 37 vs 38, P = 0.29); orphan status (38 vs 36, P = 0.56); priority review 
(37 vs 39, P = 0.66); breakthrough designation (29 vs 52, P = 0.23); accelerated approval (22 
vs 40, P = 0.13); or fast-track (46 vs 34, P=0.15). The presence of a pharmacogenomic 
biomarker in the drug label where also not statistically associated with drug value albeit drugs 
with a biomarker had a median of 44 vs 31 for those without, P = 0.06, Figure S2. Results 
were similar with ESMO-MCBS scores (Figure S3). 
relation between price and value of drugs 
We found no relation between ASCO-VF score and price as determined by US Medicare [R2 
= 0, P = 0.93] (Figure 2), nor any relation between price and value whatever the scale used 
(ASCO-VF or ESMO-MCBS) or system used to determine the price (US Medicare, US 
Veterans Health Administration or United Kingdom). 
 
discussion 
In our review of all anticancer agents approved by the FDA between 2000 and 2015, 1) only 
one third of new drugs had a meaningful clinical benefit according to the ESMO-MCBS; (2) 
drug price and clinical benefit were not related by the two scales and the three pricing 
systems; and 3) drug clinical benefit was not associated with any drug characteristics. 
Especially, we found no significant difference for personalized medicine drugs and first-in-
class drugs. 
Our results are consistent with a recent review finding that only 31% of drugs examined in 
published randomized controlled trials of four cancers (breast, colorectal, non-small cell lung 
and pancreas) had meaningful clinical benefit according to the ESMO-MCBS. [10] Another 
recent overview of clinical trials supporting FDA-approval cancer drugs (new drugs or new 
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indications) from April 2014 to February 2016 found that half met the ASCO-VF meaningful 
goals for future clinical trials for PFS and one fifth for OS. [12]  
The absence of a price–clinical benefit relation could be theoretically surprising. However, 
our results agree with previous studies. [13]. Clinical benefit was not assessable for 20% of 
drugs mainly because the drugs were approved on the basis of a single-arm trial. This 
situation is not rare in oncology, especially for orphan drugs, [14] so assessing clinical benefit  
in this situation is highly problematic— at least at the time of marketing authorization.  
The ASCO-VF and the ESMO-MCBS yielded some discrepancies which are not surprising 
given the differences in their construction and their somewhat different goals. The ASCO-VF 
is more patient-oriented and was developed to “assist in facilitating shared decision-making 
with patients about clinical benefits and costs,” [7, 8] whereas the ESMO-MCBS is more 
societal-oriented and was developed to “frame the appropriate use of limited public and 
personal resources to deliver cost-effective and affordable cancer care”. [9] Especially, the 
ESMO-MCBS uses the primary endpoint (often PFS), whereas the ASCO-VF uses OS if 
reported. However, in many cases OS was not usable to score drugs because of cross-over 
from experimental to control arm or because the OS were not enough mature at the time of 
approval. This echoes the difficulties to choose OS as a primary endpoint in many advanced 
cancer settings. 
Our study encompasses a large period of time and used two validated scales, including the 
2016 update of the ASCO-VF. However, it has some limitations. First, defining the exact 
clinical benefit of a drug is complex.[15] In this study, we used two scales that were 
previously tested and validated by various stakeholders and international experts and our 
results were similar whatever the scale used. The assessment of value depends on accurate 
reporting and analysis of clinical trial data. Notably, treatment effects have been found greater 
in published trials than in FDA documents. [16] In this study, we used FDA documents as the 
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primary source of data to limit reporting biases. The benefit of a drug refers to an benefit 
averaged over all patients being treated but it is well known that treatment effects are 
heterogeneous and some patients could derived a great benefit from a drug with a low value 
score.  
Determining the price of a drug is complex because different prices are available depending 
on the country and even within the US depending on the entity that purchases the drug. 
Furthermore, there is only limited transparency in drug pricing because the prices available 
usually do not account for managed-entry agreements or other discounts granted to buyers by 
drug manufacturers (which are not known to the public). In our study, we used two countries 
and three different pricing systems, including one with negotiated prices (US Veterans Health 
Administration). Because the results of our analyses did not depend on the choice of pricing 
system, we are confident that this limitation did not impact our study. 
The clinical benefit score of drugs is dynamic by nature as acknowledged by the ASCO [8] 
because of different reasons: 
a) Within a trial, efficacy results (especially OS results) could and will evolve with time 
as more events occur; 
b) As new clinical trials are conducted, the pooled estimate of efficacy results will also 
evolve; 
c) A drug could have subsequent supplemental approvals for new indications, each one 
being associated with a different magnitude of clinical benefit compared to its original 
indication. This point is precisely the central argument for having an indication-specific price 
of drugs.[5] 
 Here, we focused on the first indication of new drugs and evaluated the clinical benefit based 
on data submitted for approval because this reflects the entry into the market. How this 
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benefit evolves over time and with possible new indications is of interest but is out of the 
scope of our study. Recently, a live cumulative network meta-analysis was proposed to reflect 
an up-to-date summary of trial evidence for a given indication. [17] Similarly, the clinical 
benefit of a drug is relative to the control and evolves with time as more evidence and more 
alternatives are available. ESMO has planned to score all new drugs approved after January 1, 
2016 [18] and this could be incorporated in a live cumulative assessment of drugs clinical 
benefit.  
conclusion 
Patients, clinicians and policy-makers are involved in a salient debate on the clinical benefit, 
price and value of drugs. Regarding the evidence for new cancer drugs, the bar has been 
dropping, [19] which has been justified by the high benefit of new drugs. We showed, 
however, that the price of drugs was not related to their benefit to society and patients. 
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figure legends 
Figure 1. Clinical benefit of the 37 anticancer drugs approved by the US Food and Drug 
Administration (FDA) from 2000 to 2015 as evaluated by the 2016 update of the American 
Society of Clinical Oncology Value Framework Net Health Benefit (ASCO-VF NHB) and the 
European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-
MCBS). The upper scatterplot represents the distribution of the ASCO-VF NHB for each 
grade of the ESMO-MCBS and the upper-right boxplot represents the overall distribution of 
ASCO-VF NHB. The bottom-left barplot represents the overall distribution of ESMO-MCBS 
scores. 
Figure 2. Relationship between the clinical benefit of the 37 anticancer drugs approved by the 
FDA from 2000 to 2015 as evaluated by the 2016 update of the ASCO-VF NHB and the 
ESMO-MCBS and the price according to US Medicare (data on prices retrieved from 
DrugAbascus).  
Table 1. Clinical Benefit of FDA-approved new drugs for treating advanced solid cancer from 2000 to 2015 as evaluated by the 
ASCO-VF (2016 update) and the ESMO-MCBS scales. 
ASCO-VF ESMO-MCBS 
Name Year First indication Endpoint Score Endpoint Score 
Pertuzumab 2012 First-line treatment of HER-2 positive breast cancer PFS 46.8 OS 4 
Palbociclib 2015 First-line treatment of  ER-positive, HER2-negative breast cancer PFS 36.8 PFS 3 
Ixabepilone 2007 Second-line treatment of  breast cancer PFS 18.3 PFS 2 
Lapatinib 2007 Second-line treatment of  breast cancer PFS 54.6 PFS 2 
Ado-trastuzumab 2013 Second-line treatment of  HER2-positive breast cancer OS 62.4 OS 5 
Eribulin Mesylate 2010 Third-line treatment of  breast cancer OS 18.3 OS 2 
Bevacizumab 2004 First-line treatment of colorectal cancer OS 31 OS 3 
Cetuximab 2004 Second-line treatment of EGFR-expressing colorectal cancer OS 7.2 ORR 1 
Panitumumab 2006 Second-line treatment of EGFR-expressing colorectal cancer PFS 19.8 PFS 1 
Regorafenib 2012 Third treatment of colorectal cancer OS 3.4 OS 1 
Ziv-aflibercept 2012 Second-line treatment of colorectal cancer OS 16.6 OS 1 
Trifluridine and tipiracil 2015 Third-line treatment of colorectal cancer OS 49.8 OS 2 
Sunitinib  2006 Second-line treatment of gastrointestinal stromal tumor PFS 36.1 PFS 3 
Vemurafenib 2011 First-line treatment of BRAF-mutated melanoma OS 66.5 OS 4 
Afatinib 2013 First-line treatment of non-small cell lung cancer with EGFR mutations PFS 31.7 PFS 4 
Necitumumab 2015 First-line treatment of squamous non-small cell lung cancer OS 11.3 OS 2 
Erlotinib 2004 Second-line treatment of non-small cell lung cancer OS 42.1 OS 4 
Trametinib 2013 First-line treatment of BRAF-mutated melanoma PFS 52.7 PFS 4 
Dabrafenib 2013 First-line treatment of BRAF-mutated melanoma PFS 59.6 PFS 4 
Cobimetinib 2015 First-line treatment of BRAF-mutated melanoma PFS 52.2 PFS 4 
Ipilimumab 2011 Second-line treatment of melanoma OS 28.9 OS 4 
Nivolumab 2014 Second-line treatment of melanoma OS 22 OS 3 
Pemetrexed 2004 First-line treatment of mesothelioma OS 17.6 OS 3 
Ramucirumab 2014 Second-line treatment of oeso-gastric cancer OS 39.4 OS 1 
Cabazitaxel 2010 Second-line treatment of prostate cancer OS 40.5 OS 2 
Abiraterone Acetate 2011 Second-line treatment of prostate cancer OS 34.6 OS 4 
Enzalutamide 2012 Second-line treatment of prostate cancer OS 52.6 OS 4 
Radium-223  2013 Second-line treatment of prostate cancer OS 60.9 OS 5 
Sorafenib   2005 First-line treatment of renal cell carcinoma PFS 53.6 PFS 2 
Temsirolimus 2007 First-line treatment of renal cell carcinoma OS 21.6 OS 4 
Pazopanib 2009 First-line treatment of renal cell carcinoma PFS 46.3 PFS 3 
Everolimus 2009 First-line treatment of renal cell carcinoma PFS 32.8 PFS 3 
Axitinib 2012 Second-line treatment of renal cell carcinoma OS 17 PFS 3 
Trabectedin 2015 Second-line treatment of liposarcoma or leiomyosarcoma OS 14.6 PFS 3 
Vandetanib 2011 First-line treatment of thyroid cancer PFS 45.7 PFS 3 
Cabozantinib 2012 Second-line treatment of medullary thyroid cancer PFS 37.6 PFS 2 
Lenvatinib 2015 Second-line treatment of thyroid cancer PFS 59.2 PFS 2 
BRAF, B-Raf proto-oncogene; EGFR, endothelium growth factor receptor; ER, estrogen-receptor, HER-2; human epidermal growth 
factor receptor-2. 
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Table S1. Characteristics of new cancer drugs for treating solid tumors that were approved by 
the US Food and Drug Administration (FDA) from 2000 to 2015. Drug value was assessed by 
the American Society of Clinical Oncology Value Framework (ASCO-VF) and European 
Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).  
Drug value 
not assessable 
 (N= 11) 
Drug value 
assessablea 
 (N = 37) 
Indication 
  Breast cancer  1 (9)  6 (16) 
  Colorectal cancer  0 (0)  6 (16) 
  Melanoma  1 (9)  5 (14) 
  Renal cancer  0 (0)  5 (14) 
  Others 9 (82) 15 (40) 
Approval year range 
  2000–2004  2 (18)  4 (11) 
  2005–2009  1 (9) 10 (27)  
  2010–2015  8 (73) 23 (62)  
Trial phaseb  
  2  7 (70)  3 ( 8) 
  3  3 (30) 34 (92)  
Orphan designation   6 (55) 16 (43)  
Priority review  7 (64) 29 (78)  
Fast-track designation    9 (82) 18 (49)  
Breakthrough designation   2 (18) 19 (51)  
Accelerated approval    6 (55)  5 (14)  
First-in-class   5 (45)  13 (35)  
Pharmacogenomics biomarkerc  7 (64) 16 (43)  
Setting 
  First-line  4 (36) 14 (38)  
  Second-line  7 (64) 21 (57)  
  Third-line  0 (0)  2 (5) 
Data are N (%). 
a. Drug value assessable refers to drugs with both an ASCO-VF and ESMO-MCBS score.
b. Data was missing for one approval.
c. Drugs included in the FDA Table of Pharmacogenomics as of May 9, 2016
Table S2. Assessment of the value of anticancer drugs that were approved by the FDA from 2000 
to 2015, by ASCO-VF (2016 update) and ESMO-MCBS scores and endpoints used (N = 37).  
ASCO-VF 
Endpoint used, N (%) 
  OS  21 (57) 
  PFS  16 (43) 
Net Health Benefit, median [Q1–Q3] 37 [20–52] 
Clinical benefit score, median [Q1–Q3] 34 [23–42] 
Points for tail of the curve, N (%) 
  No point 19 (51)  
  PFS (16 points) 14 (38)  
  OS (20 points)  4 (11) 
Toxicity score, median [Q1–Q3] -5 [-13– -2]
Bonus scores, N (%) 
  Palliation (10 points) 2 (5) 
 QoL (10 points) 4 (11) 
  Treatment-free interval (10 points) 0 (0) 
ESMO-MCBS 
Endpoint used, N (%) 
  ORR  1 (3) 
  OS 19 (51)  
  PFS 17 (46)  
Final grade, N (%) 
  1  5 (14) 
  2  9 (24) 
  3 10 (27)  
  4 11 (30)  
  5  2 (5) 
Toxicity assessment, N (%) 
  Downgrade score from 1 point  2 (5) 
  No change 34 (92)  
  Upgrade score from 1 point  1 (3) 
OS, overall survival; PFS, progression-free survival; ORR, overall response rate; QoL, quality of 
life 
QoL assessment, N (%) 
  Downgrade score from 1 point  4 (11) 
  No change 27 (73)  
  Upgrade score from 1 point  6 (16) 
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